International Multicentric Study ARON-1

Abroad (travel likely)Recruiting

Conditions

Metastatic Renal Cell Carcinoma (mRCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ospedale di Macerata, UOC Oncologia, Province of Macerata, Macerata, Italy
Contact: Study coordinator (Matteo Santoni, MD, PhD)
Contact: Study coordinator (Giulia Sorgentoni, PhD) · giulia.sorgentoni@libero.it · +3907332573752
Contact: Principal Investigator (Matteo Santoni, MD, PhD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Carcinoma, Renal Cell · Advanced Renal Cell Carcinoma · Renal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · Scottsdale, United States

Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Metastatic Renal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Brescia, Italy · Candiolo, Italy

PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk

Renal Cell Carcinoma (RCC) · Metastatic Renal Cell Carcinoma (mRCC)

Abroad (travel likely)RecruitingPHASE2

Nanjing, China

Urine Omics Predicting IO Therapy Responses in mRCC Patients

Metastatic Renal Cell Carcinoma

Abroad (travel likely)Recruiting

Taipei, Taiwan